Winzenberg Tania, Lamberg-Allardt Christel, El-Hajj Fuleihan Ghada, Mølgaard Christian, Zhu Kun, Wu Feitong, Riley Richard D
Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Faculty of Health, University of Tasmania, Hobart, Tasmania, Australia.
BMJ Open. 2018 Jan 23;8(1):e019584. doi: 10.1136/bmjopen-2017-019584.
Our previous study-level (aggregate data) meta-analysis suggested that vitamin D supplements may be beneficial for bone density specifically in children with vitamin D deficiency. However, the misclassification of vitamin D status inherent in study-level data means that the results are not definitive and cannot provide an accurate assessment of the size of any effect. Therefore, we propose to undertake an individual patient data (IPD) meta-analysis to determine whether the effect of vitamin D supplementation on bone density in children differs according to baseline vitamin D status, and to specifically estimate the effect of vitamin D in children who are vitamin D deficient.
This study has been designed to adhere to the Preferred Reporting Items for Systematic Review and Meta-Analyses of IPD statement. We will include randomised placebo-controlled trials of vitamin D supplementation reporting bone density outcomes at least 6 months after the study commenced in children and adolescents (aged <20 years) without coexistent medical conditions or treatments causing osteoporosis. We will update the search of the original review to cover the period 2009-2017, using the same methods as the original review. Fully anonymised data on all randomised patients will be requested. Outcomes will be femoral neck, total hip, lumbar spine and proximal and distal forearm bone mineral density, and total body bone mineral content. A two-stage IPD meta-analysis will be used to examine the effect of baseline serum 25-hydroxyvitamin D (25(OH)D) on treatment effect for each bone density outcome. Restricted maximum likelihood will be used to estimate the random-effects meta-analysis models, with 95% CI for summary effects. Heterogeneity will be assessed by I and potential publication bias (small-study effects) and availability bias by funnel plots, Egger's test and Peter's test.
Ethics approval will not be required as the data are to be used for the primary purpose for which they were collected and all original individual studies had ethics approval. Results of the IPD meta-analysis will be submitted for publication in a peer-reviewed journal.
CRD42017068772.
我们之前的研究水平(汇总数据)荟萃分析表明,维生素D补充剂可能对骨密度有益,特别是对于维生素D缺乏的儿童。然而,研究水平数据中固有的维生素D状态误分类意味着结果并不确定,无法准确评估任何效应的大小。因此,我们建议进行个体患者数据(IPD)荟萃分析,以确定维生素D补充剂对儿童骨密度的影响是否因基线维生素D状态而异,并具体估计维生素D对维生素D缺乏儿童的影响。
本研究旨在遵循IPD系统评价和荟萃分析的首选报告项目声明。我们将纳入维生素D补充剂的随机安慰剂对照试验,这些试验报告了在研究开始至少6个月后,无合并症或导致骨质疏松的治疗的儿童和青少年(年龄<20岁)的骨密度结果。我们将使用与原始综述相同的方法更新原始综述的检索,以涵盖2009 - 2017年期间。将要求提供所有随机患者的完全匿名数据。结局指标将是股骨颈、全髋、腰椎以及前臂近端和远端的骨矿物质密度,以及全身骨矿物质含量。将使用两阶段IPD荟萃分析来检查基线血清25 - 羟基维生素D(25(OH)D)对每种骨密度结局治疗效果的影响。将使用限制最大似然法估计随机效应荟萃分析模型,并给出汇总效应的95%置信区间。将通过I统计量评估异质性,并通过漏斗图、Egger检验和Peter检验评估潜在的发表偏倚(小研究效应)和可获得性偏倚。
由于数据将用于其收集的主要目的,且所有原始个体研究均已获得伦理批准,因此无需伦理批准。IPD荟萃分析的结果将提交至同行评审期刊发表。
PROSPERO注册号:CRD42017068772。